{
    "nct_id": "NCT06925737",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2025-04-13",
    "study_start_date": "2025-05-13",
    "study_completion_date": "",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Ifinatamab deruxtecan"
            },
            {
                "drug_name": "Drug: Prednisone"
            },
            {
                "drug_name": "Drug: Docetaxel"
            }
        ]
    },
    "long_title": "A Phase 3, Open-label Study of Ifinatamab Deruxtecan Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (IDeate-Prostate01)",
    "last_updated": "2025-09-03",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "NA",
    "principal_investigator_institution": "Merck Sharp & Dohme LLC",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [],
    "protocol_no": "",
    "protocol_target_accrual": 1440,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Inclusion Criteria:",
        "The main inclusion criteria include but are not limited to the following:",
        "* Has diagnosis of metastatic castration-resistant prostate cancer (mCRPC)",
        "* Has prostate cancer progression while on androgen deprivation therapy (ADT) (or post bilateral orchiectomy) within 6 months prior to entering the study",
        "* Has received prior treatment with 1 or 2 androgen receptor pathway inhibitor (ARPI) and progressed during or after at least 8 weeks of treatment",
        "Exclude - Exclusion Criteria:",
        "Exclude - The main exclusion criteria include but are not limited to the following:",
        "Exclude - * History of (non-infectious) interstitial lung disease (ILD)/pneumonitis that required steroids",
        "Exclude - * Has uncontrolled or significant cardiovascular disease",
        "Exclude - * Has received prior treatment with a taxane-based chemotherapy agent for mCRPC"
    ],
    "short_title": "A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Merck Sharp & Dohme LLC",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a study medicine called ifinatamab deruxtecan (also called I-DXd or MK-2400) to treat mCRPC. The goal of this study is to learn if people who receive I-DXd live longer overall and live longer without the cancer growing or spreading than people who receive chemotherapy,",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "I-DXd",
                        "arm_internal_id": 0,
                        "arm_description": "Participants receive I-DXd 12mg/kg every 3 weeks (q3w)",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Ifinatamab deruxtecan",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Docetaxel",
                        "arm_internal_id": 1,
                        "arm_description": "Participants receive docetaxel 75 mg//m\\^2 q3w and prednisone 10 mg/day or per approved product label",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Docetaxel",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: Prednisone",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "and": [
                            {
                                "or": [
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Prostate Neuroendocrine Carcinoma"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Prostate Adenocarcinoma"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Basal Cell Carcinoma of Prostate"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Prostate Small Cell Carcinoma"
                                        }
                                    },
                                    {
                                        "clinical": {
                                            "oncotree_primary_diagnosis": "Prostate Squamous Cell Carcinoma"
                                        }
                                    }
                                ]
                            },
                            {
                                "clinical": {
                                    "age_numerical": ">=18",
                                    "gender": "Male",
                                    "disease_status": [
                                        "Metastatic"
                                    ]
                                }
                            }
                        ]
                    }
                ]
            }
        ]
    }
}